期刊文献+

继发性甲状旁腺功能亢进症的治疗 被引量:2

Treatment of Secondary Hyperparathyroidism
暂未订购
导出
摘要 尿毒症继发性甲状旁腺功能亢进(secondary hyperparathyroidism,SHPT)随着维持性透析治疗愈加严峻.准确的治疗方法可以避免SHPT导致的并发症和死亡率.常规治疗纠正高磷血症、调节血钙水平及活性维生素D的应用可以预防其发生,常规方法无效者可以选择外科手术.现就SHPT的治疗方面作一概述. The uremia secondary hyperparathyroidism (SHPT) become aggravation along with maintenance dialysis therapy. Accurate treatment method can avoid the complications and death caused by SHPT. Conventional therapy includes correcting hyperphosphatemia, regulating blood calcium levels and applying active vitamin D, which can prevent the occurrence of complications and death. If conventional methods is invalid, the doctors can choose surgery method. This paper reviews the treatment of SHPT.
作者 良良
出处 《内蒙古民族大学学报(自然科学版)》 2013年第6期718-721,共4页 Journal of Inner Mongolia Minzu University:Natural Sciences
关键词 继发性甲状旁腺功能亢进症 发病机理 临床表现 治疗 Secondary hyperparathyroidism Pathogenesis Clinical manifestations Treatment
  • 相关文献

参考文献29

  • 1Silver J, Kilav R, Naveh-Many T. Mechanisms of secondary hyper-parathyroidism[J]. Am J Physiol Renal Physiol, 2002, 283:367-F376.
  • 2London G M,Marty R,Selovaggiolo M,et al.lArterial calcifications and bone histomorphometry in end-stage renal disease [J].J Am Soc Neph-rol,2004,15:1943-19511.
  • 3Braneaecio D,Cozzoline M.Cailleni M1Hyperparathyroidism and anemiain uremic subject: A combined therapeutic ap- proaeh[J].J Am Soc Nephrol,2004,15 ( 1 ): 21,1441.
  • 4NKF-DOQI: Clinical Praltice Guidelines for Borne Metabolism and Disease in Chronic Kidney Disease[J].Am J Kidney Dis.2003,30(3):192-240.
  • 5邱承高.阿法骨化醇治疗终末期肾脏病继发甲状旁腺功能亢进疗效观察[J].华夏医学,2009,22(6):1022-1023. 被引量:1
  • 6于仲元.血液净化(第二版)[M],现代出版社,821-823,697.
  • 7谢静远,陈楠.继发性甲状旁腺功能亢进症的治疗进展[J].国际泌尿系统杂志,2006,26(1):106-109. 被引量:10
  • 8王琦,王世相.慢性肾衰竭患者继发性甲状旁腺功能亢进的治疗现状[J].国外医学(移植与血液净化分册),2004,2(5):9-11. 被引量:1
  • 9Braun J,OldendorfM,MoshageW, et a.l Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients[J].Am JKidneyDis, 1996, 27: 394-401.
  • 10Chertow GM. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients[J]. Kid- ney Int, 2002, 62:245-252.

二级参考文献124

共引文献147

同被引文献36

  • 1谢静远,陈楠.继发性甲状旁腺功能亢进症的治疗进展[J].国际泌尿系统杂志,2006,26(1):106-109. 被引量:10
  • 2耿静.慢性肾功能衰竭与继发性甲状旁腺功能亢进症关系研究新进展[J].安徽医药,2006,10(12):957-959. 被引量:4
  • 3Slatopolsky E,Brown A,Dusso A. Pathogenesis of sec- ondary hyperparathyroidism [J]. Am J Kidney Dis, 1994, 23 : 229-236.
  • 4William GG. Calcimimetic agents and secondary hyperpa- rathyroidism:rationale for use and results from clinical tri- als [J]. Pediatr Nephrol,2003,18 : 1206-1212.
  • 5Kubodera N. A new look at the most successful prodrugs for active vitamin D (D hormone) :alfacalcidol and dox- ercalciferol [J]. Molecules ,2009,14(10) :3869-3880.
  • 6Katrina R. Chronic kidney disease :Doxercalciferol is as effective as calcitriol for the treatment of secondary hy- perparathyroidism in CKD [J]. Nat Rev Nephrology,2010, 6(12) :692-701.
  • 7Holick M ,Smith E,Pincus S. Skin as the site of vitamin D synthesis and target tissue for 1,25 dihydroxyvitamin D3 [J]. Arch Dermatol, 1987,123 : 1676-1683.
  • 8Pierides A. Pharmacology and therapeutic use of vitamin D and its analogues [J]. Drugs, 1981,21:241-256.
  • 9Vitamin D and Analogs (Systemic). http://www.drugs.com/ mmx/calcijex.html?printable= 1.
  • 10St-Arnaud R, Arabian A, Akhouayri O, et al. Differential Effects of Oral Doxercalciferol (Hectorol) or Paricalcitol (Zemplar: ) in the Cyp27bl-Null Mouse Model of Ure- mia [J]. Nephron Exp Nephro1,2011,119:67-74.

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部